跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
genetically-modified fibroblasts
首页
药物
genetically-modified fibroblasts
genetically-modified fibroblasts
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Long-term cell-culture compositions and genetically modified animals derived therefrom
US 2003143737 A1
申请人: UNIV MONASH
优先权: 1999
US
Targeting vector and reconstituted cell for Cas9-mediated site-specific integration of FABP4 (adipose fatty acid-binding protein) gene and MSTN (myostatin) gene point mutation
CN 109112159 A
申请人: UNIV NORTHWEST A&F
优先权: 2018
CN
Genetically modified stem cells for treating COVID-19
CN 112553164 A
申请人: WENG BINGHUAN
优先权: 2020
CN
HACE2 knocked-in stem cells with novel coronavirus RNA interference
CN 112553163 A
申请人: WENG BINGHUAN
优先权: 2020
CN
REPROGRAMMED SMOOTH MUSCLE CELLS AND METHODS RELATED THERETO
US 20260201336 A1
申请人: UNIV EMORY
优先权: 2023
US
Preparation method and application of chemical reprogramming mesenchymal stromal cell with high expression of IL1RN/SFRP2
CN 121610446 A
申请人: HONGFANG BIOTECHNOLOGY ZHENJIANG CO LTD
优先权: 2025
CN
Preparation of chemically reprogrammed pericyte-like cells and application of chemically reprogrammed pericyte-like cells in sepsis treatment
CN 121427799 A
申请人: UNIV JIANGSU
优先权: 2025
CN
Chemical reprogramming mesenchymal stromal cell with high expression of IL10 and application of chemical reprogramming mesenchymal stromal cell
CN 121249577 A
申请人: UNIV JIANGSU
优先权: 2025
CN
药物
反馈